INDIANAPOLIS, May 21, 2026
Eli Lilly and Company announced positive topline results from its pivotal Phase 3 TRIUMPH-1 clinical trial evaluating retatrutide, an investigational triple hormone receptor agonist developed for the treatment of obesity and overweight adults with weight-related comorbidities. The study demonstrated that participants receiving the highest 12 mg dose achieved an average 28.3% body weight reduction over 80 weeks, equivalent to approximately 70.3 pounds, marking one of the strongest weight loss outcomes ever reported in a late-stage obesity trial. The data positions retatrutide as a potentially transformative therapy in the rapidly expanding obesity treatment market and further strengthens Lilly’s growing cardiometabolic portfolio.
Phase 3 TRIUMPH-1 Trial Meets Primary and Secondary Endpoints
The TRIUMPH-1 study enrolled 2,339 adults with obesity or overweight conditions without diabetes and evaluated weekly doses of retatrutide at 4 mg, 9 mg, and 12 mg compared to placebo over an 80-week period. According to the company, all dosing groups successfully met the study’s primary and key secondary endpoints, delivering statistically significant reductions in body weight and improvements in cardiometabolic risk factors.
Patients receiving the 12 mg dose achieved an average weight loss of 70.3 lbs (28.3%), while the 9 mg dose delivered 64.4 lbs (25.9%) weight reduction. Participants treated with the lower 4 mg dose still achieved clinically meaningful outcomes with an average loss of 47.2 lbs (19.0%), despite requiring only a single dose-escalation step.
Importantly, the study demonstrated that 45.3% of patients receiving the 12 mg dose achieved at least 30% body weight loss, a benchmark historically associated with bariatric surgery. Additionally, 27.2% of participants lost at least 35% of their body weight, highlighting the therapy’s strong efficacy profile in severe obesity management.
The trial also showed statistically significant improvements in multiple cardiometabolic markers, including waist circumference, triglycerides, systolic blood pressure, non-HDL cholesterol, and high-sensitivity C-reactive protein (hsCRP). Lilly stated that 65.3% of participants receiving the highest dose no longer met the BMI threshold for obesity after treatment.
Advertisement
Long-Term Extension Demonstrates Sustained Benefits
A pre-specified extension phase evaluated participants with a baseline BMI ≥35 who continued retatrutide therapy through 104 weeks. Results showed ongoing and sustained weight reduction across all treatment groups, with patients on the maximum tolerated 12 mg dose achieving an average 30.3% reduction in body weight, equivalent to approximately 85 pounds lost over two years.
Researchers noted that retatrutide’s mechanism of action may differentiate it from existing obesity therapies because it simultaneously targets GIP, GLP-1, and glucagon receptors. This triple agonist approach is designed to influence appetite suppression, glucose metabolism, fat oxidation, and energy expenditure simultaneously, potentially resulting in more substantial and sustained weight reduction.
Lead investigator Dr. Ania Jastreboff from Yale School of Medicine described the findings as a major advancement for obesity treatment, especially for patients with severe obesity who previously had limited non-surgical treatment options capable of delivering similar levels of weight reduction.
Safety Profile Supports Continued Development
The safety findings observed in TRIUMPH-1 were generally consistent with other incretin-based obesity therapies currently available on the market. The most commonly reported adverse events included nausea, diarrhea, constipation, vomiting, and upper respiratory tract infections, with most events categorized as mild to moderate in severity.
Discontinuation rates due to adverse events remained relatively low across the study, particularly in the lower-dose treatment groups. Lilly reported discontinuation rates of 4.1% for the 4 mg dose, 6.9% for the 9 mg dose, and 11.3% for the 12 mg dose, compared with 4.9% in the placebo group.
The company plans to present additional detailed findings from the TRIUMPH program at upcoming medical meetings, including the American Diabetes Association Scientific Sessions. Additional Phase 3 studies are currently evaluating retatrutide in obesity patients with type 2 diabetes, obstructive sleep apnea, cardiovascular disease, knee osteoarthritis, chronic low back pain, and liver disease.
With obesity continuing to emerge as one of the largest global pharmaceutical markets, industry analysts believe retatrutide could become a major next-generation therapy if approved by regulatory agencies worldwide.
Source: Eli Lilly press release
